Boehringer Ingelheim is one of the world’s leading familyowned pharmaceutical companies,developing medicines to address unmet needs in human and animal
Propeller Health & BI Announce New Partnership | BI US
Propeller Health, the leading digital health solution for respiratory medicine and BI announce new partnership to help people living with COPD & asthma.
BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US
BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.
Our innovation strategy focuses on developing a deep understanding of disease, identifying relevant disease mechanisms and using adequate therapeutic modalities to address them
3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US
Click here to find out more about Boehringer Ingelheim's 3FLEX® 250-Dose option & new vaccine mixing procedures, preventing major swine respiratory disease.
Standing together in support of improved access to obesity care
Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.